Next-generation protein engineering with physics: Predicting affinity, stability, selectivity, and pH-dependent binding
The landscape of protein engineering is evolving rapidly, driven by cutting-edge computational techniques that are transforming biopharmaceutical discovery and optimization. Together, we will explore groundbreaking methods that enable accurate modeling of critical physical endpoints, including thermal stability, protein-protein binding affinity, and pH sensing profiles. These innovations promise to accelerate early-stage discovery while enhancing the precision of biotherapeutic design.
In this webinar, we will introduce Schrödinger’s FEP+ Residue Scan, a next-generation tool that achieves approximately 15x speedup compared to traditional Protein FEP methods, without significant loss of accuracy. This capability enables researchers to perform large-scale residue perturbation studies with high efficiency and reliability.
We will also present a practical example of computational antibody optimization, showcasing how these tools can be applied to real-world challenges. Additionally, we will discuss how Schrödinger’s biologics services can further streamline and customize workflows, empowering scientists to tackle complex projects effectively. Join us to discover how these next-generation solutions are transforming the field of protein engineering and driving impactful innovation in the biopharmaceutical industry.
Webinar Highlights
- Overview of Schrödinger’s biologics capabilities and offerings for rational antibody design
- Key features of FEP+ Residue Scan and Protein FEP+ for protein mutational engineering
- Introduction to Schrödinger’s biologics services to lower the barrier to entry for modeling novicesbre
Our Speakers
Dan Cannon
Principal Scientist II, Schrödinger
Dr. Dan Cannon is a Principal Scientist within Schrödinger’s Applications Science team and the EU lead for biologics services in Europe. Prior to joining Schrödinger, Dan received his Ph.D. from the University of Strathclyde in Glasgow, UK, under the supervision of Prof. Tell Tuttle. In 2016, he began working at MedImmune (now AstraZeneca) in Cambridge, UK, using computational approaches for therapeutic protein design. Since joining Schrödinger in 2018, Dan has leveraged his extensive biologics expertise to enable Schrödinger customers to create and deploy cutting-edge computational workflows and design better molecules, faster.
Lingle Wang
Senior Vice President, Scientific Development, Schrödinger
Dr. Lingle Wang joined Schrödinger in 2012. He is responsible for advancing Schrödinger’s physics-based computational drug discovery platform. He obtained his Ph.D. from Columbia University working with Professors Richard Friesner and Bruce Berne on methods to quantify the role of water molecules in protein-ligand binding, enhanced sampling in biomolecular simulations, and free energy calculations. Lingle has published extensively in the areas of free energy methods development and applications in drug discovery.